Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus

Annals of Clinical Microbiology and Antimicrobials

Jennifer R. Stapp¹  Benjamin H. Gern²  Scott J. Weissman²  Xuan Qin²  Alexander L. Greninger³  Yue Tao⁴ 

[1] Department of Laboratory Medicine, University of Washington;Department of Pediatrics, Seattle Children’s Hospital, University of Washington;Seattle Children’s Microbiology Laboratory;Shanghai Children’s Medical Center, Translational Research Institute, Shanghai Jiao Tong University School of Medicine;

关键词: Staphylococcus aureus;    MSSA;    Cefazolin;    Ceftriaxone;    MIC;   

DOI  :  10.1186/s12941-018-0257-x

来源: DOAJ

【 摘 要 】

Abstract Objectives In vitro trends of cefazolin and ceftriaxone susceptibilities from pediatric clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA) between 2011 and 2016 were analyzed for surveillance. Methods Our laboratory continues to use agar disk diffusion for staphylococcal susceptibilities applying Clinical Laboratory Standard Institute’s 2012 breakpoints. Results A total of 3992 MSSA clinical isolates in the last 6 years were analyzed for their in vitro cefazolin and ceftriaxone susceptibilities. While all MSSA isolates exhibited cefazolin susceptibilities within the “susceptible” zone range, there have been a proportion of isolates with ceftriaxone susceptibilities falling in “intermediate” zones, ranging from 2.6% in 2011 to 8.3% in 2016. Conclusions Cefazolin continues to be the recommended agent for MSSA treatment at our institution, reflected by the finding that only 2% (6/321) of patients who received ceftriaxone as definitive therapy for MSSA bacteremia during the study period. We have confirmed the cefoxitin-predicted MSSA susceptibility to cefazolin, but have found concerning drifts in ceftriaxone susceptibilities by continued in vitro monitoring over the last 6 years.

【 授权许可】

Unknown